Shenzhen Rivaroxaban Co.,Ltd
Home
About us
Products
Rivaroxaban
Pharmaceutical Intermediates
Tegprazan
VeMurafenib
Anti-diabetic
Antiviral Drug
Antidepressants
Anti-cancer Drugs
High Polymer Materials
Complementary Medicines
Cardiovascular Medications
News
Blog
Contact us
Language
English
Français
Deutsch
Español
Italiano
Português
日本語
한국어
Русский
Home
>
News
LATEST NEWS
Left
The global Nifedipine Medication Market is expected to reach US$ 1,936.9 million by 2030, registering a CAGR of 8.5%
New weight loss drugs carry high price tags and lots of questions for seniors
$2.1 million awarded to research link between migraine, strokes and cardiovascular disease
Moderate
May 11, 2024
Left
read more +
Apr 03, 2024
The global Nifedipine Medication Market is expected to reach US$ 1,936.9 million by 2030, registering a CAGR of 8.5%
read more +
Feb 26, 2024
New weight loss drugs carry high price tags and lots of questions for seniors
read more +
Jan 19, 2024
$2.1 million awarded to research link between migraine, strokes and cardiovascular disease
read more +
Dec 13, 2023
Moderate
read more +
Nov 05, 2023
FDA Approves First Anti
read more +
Sep 29, 2023
Lower Doses of Statins Just as Effective in Older Adults Who Are at Greater Risk of Side Effects from the Cholesterol Drugs
read more +
Aug 22, 2023
Association of insulin use with LV remodeling and clinical outcomes in diabetic patients with heart failure and reduced ejection fraction: assessed by cardiac MRI
read more +
Aug 22, 2023
Stroke, Clot Risk Halved When Apixaban Taken Versus Rivaroxaban
read more +
Aug 20, 2023
I’ve Never Been So Panicked in My Life: Adam’s Story
read more +
Aug 18, 2023
Rivaroxaban reduces adverse kidney events in atrial fibrillation patients with CKD
read more +
Aug 16, 2023
Prescribing DOACs with specific patient populations in mind
read more +
first
1
2
3
4
5
last